Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
GLP-2 TZ is a long-acting synthetic research peptide that activates two incretin receptors from a single molecule: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). The numeral in the coded designation counts receptor targets, not hormone families: GLP-1 SM engages one incretin receptor, GLP-2 TZ two, and GLP-3 RT three. Researchers searching for glp 2 are often after one of two different things, so that distinction is worth settling first.
What follows covers the molecular design, how imbalanced and biased agonism shape behavior in cell and animal models, what recent literature has added, and how the compound sits against neighboring research peptides. Everything here concerns in-vitro and preclinical animal work, and the compound is supplied for research use only, not for human consumption.
What Is GLP-2 TZ, and What Does “GLP 2” Mean?
Two Different Things Called GLP-2
In endocrinology, glucagon-like peptide-2 is a 33-amino-acid proglucagon-derived hormone from intestinal L-cells, studied for trophic signaling in the gut epithelium. It is a separate molecule with its own receptor (GLP-2R), and the peptide supplied as GLP-2 TZ is not an analog of it. Here the “2” is shorthand for dual incretin receptor engagement, placing the compound among the unimolecular dual agonists built on a GIP-derived backbone. A search for glp 2 peptide can land on either subject, so any comparison of published data has to keep them apart.
Molecular Design
GLP-2 TZ is a synthetic 39-residue linear peptide, C-terminally amidated, with three design features that define its bench behavior. Non-natural alpha-aminoisobutyric acid (Aib) residues at positions 2 and 13 block cleavage by dipeptidyl peptidase-4 (DPP-4), which inactivates native GIP and GLP-1 within minutes of release. A C20 fatty diacid conjugated through a gamma-glutamate and dual AEEA linker to a mid-sequence lysine supports reversible albumin binding and slows renal clearance. The resulting half-life runs to days rather than minutes, making sustained receptor-occupancy experiments practical without continuous infusion.
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported Value |
|---|---|
| Designation | GLP-2 TZ |
| Class | Unimolecular dual incretin receptor agonist |
| Sequence length | 39 amino acids, linear, C-terminally amidated |
| Approximate molecular weight | Roughly 4.8 kDa for the lipidated 39-residue peptide |
| Receptor targets | GIPR and GLP-1R |
| Non-natural residues | Aib at positions 2 and 13 |
| Lipidation | C20 fatty diacid via gamma-glutamate and dual AEEA linker |
| Protease resistance | DPP-4 resistant (position-2 Aib) |
| Not to be confused with | Glucagon-like peptide-2, a separate 33-residue gut hormone |
Mechanism at Two Incretin Receptors
Imbalanced Agonism
Describing GLP-2 TZ as a compound that activates both receptors understates the pharmacology. Reported affinity and potency at GIPR are comparable to native GIP, while activity at GLP-1R is roughly an order of magnitude weaker than native GLP-1 in binding studies. The molecule is therefore an imbalanced dual agonist weighted toward GIPR, and comparisons against single-receptor reference compounds have to account for that asymmetry rather than assume matched engagement.
Biased Signaling at GLP-1R
At GLP-1R, signaling favors cAMP generation over beta-arrestin recruitment. Less beta-arrestin coupling means less receptor internalization and slower desensitization, so the receptor stays available at the cell surface longer. In cellular assays this appears as sustained cAMP accumulation where a balanced agonist would show progressive signal decay.
Downstream Convergence
Both receptors couple predominantly to Gs and raise intracellular cAMP, activating protein kinase A and Epac2, converging in beta-cell models on glucose-dependent insulin exocytosis. That glucose dependence defines incretin pharmacology: the insulinotropic signal diminishes as glucose falls toward baseline, unlike secretagogues acting independently of ambient glucose. Single-concentration assays miss it, which is why islet and beta-cell experiments run across a glucose gradient.
What 2025 and 2026 Research Has Added
Signaling Bias as a Design Variable
Work published in Cell Reports Medicine in 2025 reported that biasing agonism at both GLP-1R and GIPR toward cAMP, and away from beta-arrestin recruitment, shifted metabolic endpoints in rodent models relative to unbiased comparators, with dual biased agonism giving the largest separation; a 2026 Molecular Metabolism report described a once-weekly signaling-biased dual agonist along similar lines. Bias, not only receptor coverage, is now an independent variable in study design.
GIPR Agonism Versus Antagonism
The longest-running puzzle in this field is that both GIPR agonism and GIPR antagonism have been reported to reduce food intake and body weight in rodent models. A 2025 Nature Metabolism study reported in male mice that the two act through different mechanisms: agonism worked through GABAergic GIPR-positive neurons and remained effective without GLP-1R signaling, while antagonism required intact GLP-1R signaling, with transcriptional changes in the dorsal vagal complex running in opposing directions. A 2025 review in Diabetes revisited the controversy across the wider literature.
Where GIPR Signaling Acts
Two further reports extended the map of GIPR-expressing tissues: one described GIPR activation driving futile calcium cycling in white adipose tissue of mice, raising energy expenditure, and a 2025 Cell Metabolism paper reported GIPR signaling in oligodendrocytes modulating the central response to GLP-1R agonism. GIPR is evidently not solely a beta-cell receptor, and effects attributed to dual agonism may originate outside the islet.
How GLP-2 TZ Compares to Neighboring Research Peptides
Positioning against related compounds is often the experiment itself. Running GLP-2 TZ beside a single-receptor agonist isolates the GIPR contribution; beside a triple agonist it isolates the glucagon receptor contribution, since that class adds GCGR engagement to the same dual incretin base. Amylin-class peptides sit outside the incretin family and serve as independent comparators in energy-balance models.
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Research Peptide | Receptor Targets | Class | Isolates in Comparison |
|---|---|---|---|
| GLP-1 SM | GLP-1R | Single incretin receptor agonist | Baseline GLP-1R pharmacology |
| GLP-2 TZ | GIPR and GLP-1R | Dual incretin receptor agonist | Contribution of GIPR engagement |
| GLP-3 RT | GIPR, GLP-1R, GCGR | Triple receptor agonist | Contribution of glucagon receptor activity |
| Cagrilintide | Amylin and calcitonin receptors | Long-acting amylin analog | Non-incretin comparator pathway |
Two controls recur across this literature: receptor-knockout lines or selective antagonists, needed before any effect can be attributed to one receptor rather than the other, and profiling against both rodent and human receptor orthologs, since species differences in GIPR pharmacology are substantial.
Laboratory Handling and Material Verification
A 39-residue peptide carrying non-natural residues and a lipid conjugate offers more room for synthesis-related impurities than a short native sequence, so mass spectrometry identity confirmation alongside HPLC purity determination is the minimum standard. Net peptide content, as distinct from gross vial mass, should drive molar calculations, since counterion and residual moisture otherwise put a systematic error into every concentration. Reading those figures is covered in the COA and purity guide, and batch records appear on the certificates page.
Lyophilized material is held cold, dry, and protected from light. Reconstituting a 10 mg vial with 2 mL of bacteriostatic water gives a 5 mg/mL stock, while 5 mL gives 2 mg/mL. Solutions are far shorter-lived than the powder, and repeated freeze-thaw cycling is avoided in stability-sensitive work. Solvent technique is covered in the bacteriostatic water guide and the chemistry in the solubility and reconstitution article.
In summary, what is glp 2 tz in the Rejuven8 catalog is a dual incretin receptor research peptide: imbalanced toward GIPR, biased toward cAMP at GLP-1R, and extended in duration by albumin binding. Its value as a laboratory tool is that it holds the ratio between two pharmacologies fixed inside one molecule, which a two-compound combination cannot do. GLP-2 TZ and the rest of the research peptide catalog are supplied for laboratory investigation only.
Frequently Asked Questions
What is GLP-2 TZ?
GLP-2 TZ is a synthetic 39-amino-acid research peptide that activates both the GIP receptor and the GLP-1 receptor from one molecule. The numeral counts incretin receptors engaged, not glucagon-like peptide-2.
Is GLP-2 TZ the same as the GLP 2 peptide hormone?
No. Glucagon-like peptide-2 is a 33-amino-acid gut hormone acting at its own receptor, GLP-2R. GLP-2 TZ is a dual incretin receptor agonist on a GIP-derived backbone. The names are similar; the molecules and targets are not.
How does GLP-2 TZ differ from GLP-1 SM?
GLP-1 SM engages one incretin receptor and GLP-2 TZ engages two. Running them side by side in the same model isolates what GIP receptor activation contributes at matched GLP-1R occupancy.
What does imbalanced agonism mean?
It means the compound does not activate both receptors with equal potency. Reported activity at GIPR is comparable to native GIP, while activity at GLP-1R is roughly an order of magnitude weaker than native GLP-1, weighting the pharmacology toward GIPR.
Why is GLP-2 TZ resistant to DPP-4?
The alpha-aminoisobutyric acid substitution at position 2 removes the cleavage site DPP-4 uses to inactivate native incretins. With albumin binding through a C20 fatty diacid, the circulating half-life extends from minutes to days in animal models.
What models are used in dual incretin agonist research?
Isolated islets and INS-1 or MIN6 beta-cell lines for secretion work, diet-induced obese and genetically diabetic rodent models for in-vivo studies, and receptor-knockout lines or selective antagonists for attributing an effect to one receptor.
References and Further Reading
- Finan B and colleagues reported unimolecular dual incretin agonists in Science Translational Medicine in 2013, establishing the template for this compound class. PubMed: unimolecular dual incretin agonist
- Baggio LL and Drucker DJ have published extensively on the physiology of GIP and GLP-1. PubMed: biology of incretins GLP-1 and GIP
- Studies of signaling bias at GLP-1R and GIPR, including 2025 and 2026 reports on cAMP-biased dual agonism. PubMed: biased agonism GLP-1R GIPR
- Nature Metabolism, 2025: GIPR agonism and antagonism reduce food intake through different mechanisms in male mice. PubMed: GIPR agonism antagonism different mechanisms mice
- Reports on GIPR signaling outside the islet, including adipose calcium cycling and central GIPR expression. PubMed: GIP receptor adipose tissue energy expenditure
- Cryo-electron microscopy structures of GIPR and GLP-1R bound to peptide agonists, showing how one sequence accommodates two class B receptors. PubMed: cryo-EM structure GIP receptor GLP-1 receptor agonist
- Reviews revisiting the GIP receptor agonism versus antagonism question in preclinical metabolic research. PubMed: GIP receptor agonism antagonism controversy
